Biomarker Discovery Outsourcing Services Market Analysis

Biomarker Discovery Outsourcing Services Market Analysis

To get key market trends

  Download Free Sample

Based on type, the market is segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints, and other types. The surrogate endpoints are expected to lead the market, projecting the highest revenue of USD 16.2 billion by 2032.
 

• The surrogate biomarkers play a pivotal role in predicting treatment efficacy and safety during drug development. They act as indirect measures representing clinical outcomes.
   
• Also, the reliance on surrogate endpoints streamlines clinical trials by accelerating decision-making and reducing development costs. Thus, the outsourcing services focusing on the identification and validation of surrogate endpoints have become integral, thereby driving the market progress.

Based on service, the biomarker discovery outsourcing services market is classified into genomics biomarker services, proteomics biomarker services, bioinformatics biomarker services, and other services. The genomics biomarker services segment dominated the market accounting for the largest share of 44.4% in 2023.
 

• Genomics biomarker services dominate biomarker discovery outsourcing, leveraging advanced technologies to identify vital biomarkers for precision medicine and drug development.
   
• The precision and depth offered by genomics tools, including next-generation sequencing, empower efficient identification of genetic variations linked to diseases. For instance, in January 2021, Crown Bioscience has enhanced its advanced next-generation sequencing (NGS) capabilities and introduced exclusive NGS panel services. This offers pharmaceutical partners greater insights into drug mechanisms of action, enabling the development of predictive biomarkers. These expanded services aim to enhance accuracy, sensitivity, and speed in advancing new agent programs by uncovering MOAs and predictive biomarkers.
   

Based on therapeutic area, the biomarker discovery outsourcing services market is classified into oncology, cardiology, neurology, autoimmune disease, and other therapeutic areas. The oncology segment is anticipated to grow at CAGR of 11.6% between 2024 and 2032.
 

• Cancer is a major global health concern leading to significant research and investments in oncology biomarkers, driven by the prevalence of diverse types of cancers such as lung, breast, prostate, and colorectal cancers among others.
   
• Therefore, the identification of genomic biomarkers, notably mutations in specific genes such as EGFR, KRAS, and BRCA, holds paramount significance in oncology. Thus, the precision in detecting these cancer biomarkers is facilitated by advanced technologies such as next-generation sequencing and other genomic methodologies. This is expected to influence the management of various cancer types, thereby supplementing the market progress.
   

Based on end-use, the biomarker discovery outsourcing services market is classified into pharmaceutical companies, biotechnology companies, and other end-users. The biotechnology companies dominated the market in 2023 and is expected to show similar trend over the analysis period.
 

• Biotechnology companies collaborate with various CROs to outsource biomarker services, spearheading innovative approaches in biomarker identification and validation. Their specialized expertise and cutting-edge technologies position them as key players, catering to the growing demand for precision medicine solutions.
   
• Pioneering biotech companies shape biomarker-driven drug development, steering the market and strengthening their crucial role in the outsourced biomarker discovery services landscape.

 In 2023, North America held a significant market share in the global biomarker discovery outsourcing services market and is anticipated to dominate the market throughout the forecast period with a CAGR of 12.3%.
 

• North America exerts significant influence over the market, standing as the primary hub for innovative pharmaceutical and biotechnology research.
   
• The region exhibits advanced infrastructure, a robust healthcare ecosystem, and a high concentration of leading outsourcing service providers.
   
• Factors such as strategic collaborations, technological advancements, and substantial investment in research and development further consolidate North America's dominance.
   
• The presence of key players, coupled with a proactive regulatory environment, positions the region as a frontrunner in shaping the trajectory of biomarker discovery outsourcing services globally.